Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVE-Treg and Low-Dose IL-2 for Steroid-Refractory Chronic GVHD
NCT06991361Phase 1Recruiting
- Start
- May 2026
- Primary completion
- May 2029
- Modality
- Allogeneic CAR-T, Regulatory T Cells (Tregs), Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of EVE-Treg in chronic graft-versus-host disease (cGVHD) (3 arms). Primary endpoint: Safety of EVE-Treg at 5 weeks. Started May 2026; status: recruiting.
02
Drugs
EVE-Treg
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06991361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06991361.